Medtronic Secures FDA Approval for Advanced Defibrillation Lead

Medtronic has received approval from the U.S. Food and Drug Administration for its OmniaSecure defibrillation lead to be used in the left bundle branch area of the heart.

The device connects to implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy defibrillators (CRT-Ds) to treat abnormal heart rhythms, including arrhythmia. This expanded indication makes it the first defibrillation lead approved for left bundle branch placement.

This approach supports conduction system pacing, which activates the heart’s natural electrical pathways and may offer a more physiologic alternative to traditional right ventricular pacing.

Approval was supported by results from the LEADR LBBAP trial, demonstrating the device’s safety and effectiveness. Medtronic had previously received FDA clearance for right ventricular placement and launched the product in the U.S. earlier this year.

The development marks a significant step forward in cardiac rhythm management, offering patients a more advanced and synchronized treatment option.

31-03-2026